Panel Backs Glaxo Rare-Cancer Therapy; Rejects Merck Drug

GlaxoSmithKline Plc’s drug for a rare, often deadly form of cancer won the backing of U.S. advisers, while a similar treatment from Merck & Co. and Ariad Pharmaceuticals Inc. failed to gain support.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.